PERIPHERAL T-CELL LYMPHOMA

This study tests whether combining the drug golidocitinib with either mitoxantrone liposome or chidamide can safely shrink tumors in people with peripheral T-cell lymphoma that has returned or not responded to prior therapy. About 101 adults will take part. The goal is to find th…

This study looks at two options for people with peripheral T-cell lymphoma whose cancer went away after their first treatment. One group will get a stem cell transplant using their own cells, and the other group will just be watched closely. The goal is to see which approach help…

This study looks at two types of stem cell transplants for people with a rare blood cancer called peripheral T-cell lymphoma that only partially improved after first treatment. One group gets their own stem cells back, while the other gets stem cells from a matched donor. The goa…

This study tests a new type of CAR-T cell therapy that targets two cancer markers at once, designed to work better against blood cancers that have come back or not responded to other treatments. About 96 adults with various blood cancers will receive a custom treatment based on t…

This study tests whether adding a JAK inhibitor (ruxolitinib) to an immunotherapy drug (pembrolizumab) is safe and effective for people with certain types of lymphoma that have come back or not responded to treatment. About 53 adults with relapsed or refractory Hodgkin or non-Hod…

This study tests a new treatment for people with a rare blood cancer called peripheral T-cell lymphoma that has returned or not improved with standard therapy. Researchers take a patient's own immune cells, modify them in a lab to recognize and attack cancer cells, and then infus…

This early-phase trial tests whether a patient's own immune cells, modified in a lab to recognize and attack a protein called CCR4 on cancer cells, can safely treat certain T-cell lymphomas that have not responded to or returned after standard therapy. About 60 adults with relaps…

This study tests whether adding the experimental drug lacutamab to standard chemotherapy (GemOx) helps people with a rare type of blood cancer called peripheral T-cell lymphoma that has returned or not improved after prior treatment. About 56 adults whose cancer cells have a spec…

This program provides the experimental drug selinexor to people with multiple myeloma, lymphoma, sarcoma, or other cancers who have run out of standard treatments and cannot join a clinical trial. The goal is to offer a potential treatment option when nothing else is left. Patien…

This study tests whether the drug golidocitinib can help keep peripheral T-cell lymphoma (a rare blood cancer) from returning in patients who already responded well to their first chemotherapy but cannot have a stem cell transplant. About 136 adults will receive either golidociti…

This study tests a new drug called golidocitinib against standard treatments for adults with a rare blood cancer (peripheral T-cell lymphoma) that has returned or not responded to prior therapy. About 218 participants will be randomly assigned to receive either golidocitinib or a…

This study is for people with peripheral T-cell lymphoma whose cancer did not shrink or got worse after standard first chemotherapy. It compares two approaches: a stem cell transplant from a healthy donor (allogeneic HSCT) or other rescue treatments. The goal is to see which opti…

This early-stage trial tests a specially modified virus (VSV-hIFNβ-NIS) designed to kill cancer cells without harming healthy ones, given alongside two immunotherapy drugs (ipilimumab and cemiplimab). It is for adults with certain types of T-cell lymphoma that have come back or n…

This study tests whether combining two drugs—sintilimab and chidamide—can help people with a type of blood cancer called peripheral T-cell lymphoma that has come back or not responded to prior treatment. About 51 adults aged 18 to 75 will receive the drug combination. The goal is…

This study tests a new combination of two targeted drugs (linperlisib and chidamide) against standard chemotherapy for people with peripheral T-cell lymphoma, a rare blood cancer. The trial involves about 134 adults aged 18-80. The goal is to see if the new combo works better at …

This study tests a new drug called CCS1477 (inobrodib) in people with advanced blood cancers like leukemia, lymphoma, and multiple myeloma. The goal is to see if the drug is safe and can help control the disease. About 250 participants who have tried standard treatments without s…

This study tests a new drug called golidocitinib for people newly diagnosed with peripheral T-cell lymphoma, a rare blood cancer. The drug is given alone or with standard chemotherapy (CHOP) to see if it can better control the disease. About 30 adults will take part, and research…

This early-stage trial tests a new drug called ST-001 in people with T-cell non-Hodgkin lymphoma whose cancer has returned or not responded to prior treatments. The main goal is to find the safest dose and understand side effects. About 46 participants will receive the drug throu…

This study is for people newly diagnosed with a rare type of blood cancer called peripheral T-cell lymphoma (PTCL). It compares two experimental drug combinations (Bel-CHOP and Fol-COP) to the standard chemotherapy (CHOP) to see which works better at stopping the cancer from grow…

This study tests whether the drug ruxolitinib, taken as a maintenance therapy after a stem cell transplant, can help prevent T-cell lymphoma from coming back and reduce the risk of graft-versus-host disease (GVHD), a common complication where donor cells attack the patient's body…

This study tests an experimental drug called HH2853 for people with certain types of blood cancer (non-Hodgkin's lymphoma) or advanced solid tumors that have come back or not responded to treatment. The goal is to find the safest dose and see if the drug can shrink tumors. About …

This study tests whether two drugs, cidabenamine and azacitidine, can keep high-risk peripheral T-cell lymphoma from coming back after a stem cell transplant. About 40 adults aged 18 to 70 will receive this maintenance therapy. The goal is to see if the treatment improves surviva…

This early-stage study tests whether specially modified immune cells from healthy donors can safely fight certain lymphomas (Hodgkin and some non-Hodgkin types) that have returned or not responded to standard therapy. The cells are designed to target a protein called CD30 on canc…

This study will follow about 3,000 people in China with peripheral T-cell lymphoma, a rare blood cancer. Researchers will look at how the disease is treated in everyday practice, what genetic changes occur, and how long patients live. The goal is to learn more about the disease a…

This study looks at how the body processes venetoclax when the tablet is crushed and mixed into a liquid for children and young adults with blood cancers like leukemia or lymphoma. About 30 participants who already take venetoclax this way will have their blood levels measured. T…